Search Results - "Khosravan, R."

Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers by Becker, M. A., Kisicki, J., Khosravan, R., Wu, J., Mulford, D., Hunt, B., MacDonald, P., Joseph-Ridge, N.

“…In order to evaluate the safety, pharmacological properties, and urate-lowering efficacy of febuxostat, a non-purine, selective inhibitor of xanthine oxidase,…”
Get full text

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer by Lee, K.-W., Park, S. R., Oh, D.-Y., Park, Y.-I., Khosravan, R., Lin, X., Lee, S.-Y., Roh, E.-J., Valota, O., Lechuga, M. J., Bang, Y.-J.

“…Summary Background We evaluated the maximum tolerated dose (MTD) and safety of sunitinib plus capecitabine/cisplatin (XP) or capecitabine/oxaliplatin (XELOX)…”
Get full text

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer by Gómez-Martín, C., Salazar, R., Montagut, C., Gil-Martín, M., Núñez, J. A., Puig, M., Lin, X., Khosravan, R., Tursi, J. M., Lechuga, M. J., Bellmunt, J.

“…Summary Background This phase I, open-label, dose-escalation study examined the safety, maximum tolerated dose (MTD), and pharmacokinetics of sunitinib plus…”
Get full text

7165 POSTER Sunitinib (SU) Pharmacokinetic (PK)-Pharmacodynamic (PD) Modeling With Respect to Safety and Efficacy Endpoints in Asian Patients With Gastrointestinal Stromal Tumour (GIST) or Renal Cell Carcinoma (RCC) in Pursuit of a Therapeutic Window by Khosravan, R, Mugundu, G, Agata, N, Ueda, E, Nishida, T, Akaza, H

Get full text

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors by Leong, S., Eckhardt, S. G., Chan, E., Messersmith, W. A., Spratlin, J., Camidge, D. R., Diab, S., Khosravan, R., Lin, X., Chow Maneval, E., Lockhart, A. C.

“…Purpose This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib…”
Get full text

51 (PB039): Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship for Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α, Confirms Best-in-class Potential in Treatment of Renal Cell Carcinoma by Ghasemi, M., Khosravan, R., Kim, J.Y., Seitz, L., Foster, P., Agoram, B.

Get full text

Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects by Khosravan, R., Grabowski, B., Wu, J. T., Joseph‐Ridge, N., Vernillet, L.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects by Khosravan, R., Kukulka, M., Wu, J. T., Joseph‐Ridge, N., Vernillet, L.

“…Background Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients…”
Get full text

Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects by Khosravan, R., Erdman, K., Vernillet, L., Wu, J. T., Joseph‐Ridge, N., Umeda, S., Mulford, D.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

Sunitinib (SU) pharmacokinetic (PK)–pharmacodynamic (PD) modeling with respect to safety and efficacy endpoints in Asian patients (pts) with gastrointestinal stromal tumor (GIST) or renal cell carcinoma (RCC) in pursuit of a therapeutic window by Khosravan, R., Mugundu, G., Agata, N., Ueda, E., Nishida, T., Akaza, H.

“…Abstract only…”
Get full text

Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis by Khosravan, R., Toh, M., LaFargue, J., Ni, G., Bello, C.

“…Abstract only…”
Get full text

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment by Mayer, Michael D, Khosravan, Reza, Vernillet, Laurent, Wu, Jing-Tao, Joseph-Ridge, Nancy, Mulford, Darcy J

“…To assess the safety, pharmacokinetics, and pharmacodynamics of febuxostat in subjects with normal renal function or renal impairment, febuxostat (80 mg/d) was…”
Get full text

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase by Khosravan, Reza, Grabowski, Brian A., Mayer, Michael D., Wu, Jing-Tao, Joseph-Ridge, Nancy, Vernillet, Laurent

“…To assess the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, and safety of febuxostat at steady state, multiple once‐daily 80‐mg oral…”
Get full text

PI-55 by Khosravan, R., Wu, J., Joseph‐Ridge, N., Vernillet, L.

“…AIMS The objective of this study was to evaluate the population (pop) PK and PD of febuxostat (FBX), a non‐purine selective inhibitor of xanthine oxidase, in…”
Get full text

PI-55Population pharmacokinetics and pharmacodynamics of febuxostat in a phase-III study of patients with gout by KHOSRAVAN, R, WU, J, JOSEPHRIDGE, N, VERNILLET, L

Get full text

Transbuccal permeation of a nucleoside analog, dideoxycytidine: effects of menthol as a permeation enhancer by Shojaei, Amir H, Khan, Mansoor, Lim, Gerald, Khosravan, Reza

“…The use of a safe and effective permeation enhancer is paramount to the success of a buccal drug delivery system intended for systemic drug absorption. The…”
Get full text